Telephone-Based Support Programs for People With Epilepsy

Description

This is a two-arm randomized controlled trial to compare telephone-based depression self-management (UPLIFT) to telephone-based support groups (BOOST). A sample of 120 English- and Spanish-speaking people with epilepsy (PWE) with elevated depressive symptoms will be enrolled. Both interventions are 8-week programs delivered in one-hour weekly sessions to groups of about 6 participants. Changes in depressive symptoms, quality of life and seizures will be assessed over 12 months. The trial will also examine mediators and moderators of treatment effects.

Conditions

Epilepsy

Study Overview

Study Details

Study overview

This is a two-arm randomized controlled trial to compare telephone-based depression self-management (UPLIFT) to telephone-based support groups (BOOST). A sample of 120 English- and Spanish-speaking people with epilepsy (PWE) with elevated depressive symptoms will be enrolled. Both interventions are 8-week programs delivered in one-hour weekly sessions to groups of about 6 participants. Changes in depressive symptoms, quality of life and seizures will be assessed over 12 months. The trial will also examine mediators and moderators of treatment effects.

NYU Managing Epilepsy Well (MEW) Study: A Randomized Controlled Trial of Telephone-Based Support for People With Epilepsy

Telephone-Based Support Programs for People With Epilepsy

Condition
Epilepsy
Intervention / Treatment

-

Contacts and Locations

New York

NYU Langone Health, New York, New York, United States, 10016

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * adult (≥18 years of age);
  • * diagnosed with epilepsy for at least one year;
  • * fluent in English or Spanish;
  • * elevated depressive symptoms (PHQ-9 score ≥10);
  • * willing to participate in audiotaped group telephone sessions
  • * severe depressive symptoms (PHQ-9 ≥20);
  • * active suicidal ideation (PHQ-9 item #9 ≥1 or otherwise reported during screening);
  • * active psychotic disorder (psychiatric diagnosis or antipsychotic medications in the EHR);
  • * significant cognitive impairment (indicated in EHR or evident during screening)

Ages Eligible for Study

18 Years to 99 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

NYU Langone Health,

Tanya Spruill, PRINCIPAL_INVESTIGATOR, NYU Langone Health

Daniel Friedman, MD, PRINCIPAL_INVESTIGATOR, NYU Langone Health

Study Record Dates

2025-08-31